AMGN vs. PFE: Amgen vs. Pfizer Stock Comparison

November 11, 2026

How do Amgen (AMGN) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Company profile comparison for Amgen (AMGN) and Pfizer (PFE)
Profile Item	AMGN	PFE
Name	Amgen Inc. Common Stock	Pfizer Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	249.05 billion USD	167.52 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 17, 1983	June 1, 1972
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AMGN

PFE

GSPC

Amgen (AMGN) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Amgen (AMGN) and Pfizer (PFE). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Amgen (AMGN) and Pfizer (PFE). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
Total Return (1Y)	48.82%	28.65%
Total Return (3Y, Annualized)	24.31%	6.41%
Total Return (5Y, Annualized)	20.67%	-3.98%

Risk Profile

Drawdown History

AMGN

PFE

GSPC

Amgen (AMGN) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Amgen (AMGN) and Pfizer (PFE). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
Volatility (1Y, Annualized)	29.12%	21.72%
Beta (5Y)	0.43	0.35
Max Drawdown (5Y)	-24.86%	-58.96%
Avg. Volume (3M)	2.76M	33.67M

Risk-Adjusted Performance

Risk-Return Positioning

AMGN and PFE are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
Sharpe Ratio (1Y)	1.53	1.12
Sortino Ratio (1Y)	2.36	1.73

Profitability

ROE (TTM)

Amgen (AMGN) at 78.35% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for AMGN.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max: 109.18%
AMGN: 78.35%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max: 109.18%
Q3: 6.23%
PFE: 4.47%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Amgen (AMGN) at 24.14% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN: 24.14%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max: 18.05%
PFE: 6.34%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max: 83.12%
AMGN: 35.79%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max: 83.12%
PFE: 33.38%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
ROE (TTM)	78.35%	4.47%
ROA (TTM)	8.91%	5.59%
Net Margin (TTM)	24.14%	6.34%
Operating Margin (TTM)	35.79%	33.38%
Gross Margin (TTM)	72.47%	74.90%

Growth

Revenue Growth

Amgen (AMGN) at 9.95% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their Revenue Growth across different time periods.

EPS Growth

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Pfizer (PFE) at -3.55% is closer to the peer norm — faster per-share earnings growth for AMGN.

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
Revenue Growth (YoY)	9.95%	-1.65%
Revenue Growth (3Y CAGR)	11.77%	-14.80%
EPS Growth (YoY)	88.23%	-3.55%
EPS Growth (3Y CAGR)	5.52%	-37.12%

Financial Strength

Current Ratio (MRQ)

Both Amgen (AMGN) at 1.48 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AMGN: 1.48
Min: 0.10

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
PFE: 1.42
Min: 0.10

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: Pfizer (PFE) at 0.71 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN: 3.76
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max: 1.42
PFE: 0.71
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
Current Ratio (MRQ)	1.48	1.42
Debt / Equity (MRQ)	3.76	0.71
Net Debt / EBITDA	2.31	1.97

Dividends

Dividend Yield (TTM)

Both Amgen (AMGN) at 2.16% and Pfizer (PFE) at 7.30% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN: 2.16%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE: 7.30%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Amgen (AMGN) reports 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN: 57.62%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE: 245.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
Dividend Yield (TTM)	2.16%	7.30%
Dividend Payout Ratio (TTM)	57.62%	245.71%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 26.69 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max: 85.34
Q3: 43.46
AMGN: 26.69
Median: 26.69
Q1: 13.30
Min: 0.07

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max: 85.34
Q3: 43.46
PFE: 41.99
Median: 26.69
Q1: 13.30
Min: 0.07

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Amgen (AMGN) at 6.40 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max: 58.18
Q3: 25.77
Median: 7.30
AMGN: 6.40
Q1: 3.01
Min: 0.01

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
PFE: 2.63
Min: 0.01

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Pfizer (PFE) at 1.88 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN: 17.35
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max: 13.53
Q3: 6.54
Median: 3.25
PFE: 1.88
Q1: 1.69
Min: -5.59

Amgen (AMGN) vs. Pfizer (PFE): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Pfizer (PFE)
Metric	AMGN	PFE
P/E Ratio (TTM)	26.69	41.99
P/S Ratio (TTM)	6.40	2.63
P/B Ratio (MRQ)	17.35	1.88
Free Cash Flow Yield (TTM)	2.96%	7.76%